In a patient with recent acute myocardial infarction, ejection fraction 37 %, on norepinephrine infusion, and a high burden of premature ventricular complexes that degenerate into supraventricular tachycardia, is adenosine safe to give?

Adenosine Should NOT Be Given in This High-Risk Patient

In a patient with recent acute MI, reduced ejection fraction (37%), on vasopressor support, and high PVC burden transitioning to SVT, adenosine carries unacceptable risks and synchronized cardioversion is the preferred approach.

Critical Safety Concerns with Adenosine in This Context

The FDA drug label explicitly warns that adenosine should be avoided in patients with symptoms or signs of acute myocardial ischemia (e.g., unstable angina or cardiovascular instability), as these patients are at greater risk of serious cardiovascular reactions including fatal cardiac arrest, sustained ventricular tachycardia, and myocardial infarction 1. Your patient meets multiple high-risk criteria:

• Recent acute MI (acute ischemic state)
• Hemodynamic instability (requiring norepinephrine)
• Reduced EF 37% (impaired ventricular function)
• High PVC burden (electrical instability)

Why Adenosine Is Particularly Dangerous Here

Pro-arrhythmic Risk in Acute MI

Adenosine can precipitate atrial fibrillation that may conduct rapidly to the ventricles and even cause ventricular fibrillation 2. In a patient with recent MI and high PVC burden, the myocardium is already electrically unstable. Case reports document VF requiring immediate defibrillation following adenosine administration, even in structurally normal hearts 3, 4. Your patient's compromised myocardium substantially amplifies this risk.

Hemodynamic Collapse

Adenosine is a potent peripheral vasodilator that can induce significant hypotension 1. The risk is particularly high in patients with:

• Cardiovascular instability (your patient is already on norepinephrine)
• Reduced ejection fraction
• Recent MI

The FDA label specifically warns about hypotension risk in patients with "cardiovascular instability" 1. Adding adenosine to a patient requiring vasopressor support could precipitate profound shock.

Post-Conversion Arrhythmias

The 2015 ACC/AHA/HRS SVT guidelines note that patients often have atrial or ventricular premature complexes immediately after conversion that may induce further episodes of arrhythmia 2. In your patient with already high PVC burden, adenosine could trigger sustained ventricular arrhythmias. Research shows adenosine induces PVCs or VT in 47-67% of patients 5, 6, with polymorphic VT documented in multiple case reports 7, 8.

Recommended Management Algorithm

If Hemodynamically Unstable

Proceed directly to synchronized cardioversion 2:

• Do not attempt adenosine
• Sedate appropriately if time permits
• Start with device-recommended energy (typically 50-100J for SVT)
• Have defibrillator ready for immediate unsynchronized shock if VF develops

If Hemodynamically Stable (Unlikely Given Norepinephrine Use)

1. First-line: Vagal maneuvers (modified Valsalva in supine position) 2
2. If vagal maneuvers fail: Synchronized cardioversion 2
   • Skip adenosine entirely given the contraindications
3. Alternative pharmacologic options (if cardioversion not immediately available):
   • IV beta-blockers (if not contraindicated by hypotension)
   • IV amiodarone (150 mg over 10 min) 9

Critical Preparation

Regardless of approach, ensure:

• Defibrillator immediately available at bedside 2, 1
• Resuscitation equipment ready
• Continuous cardiac monitoring
• IV access secured

Common Pitfalls to Avoid

1. Don't assume "SVT = adenosine" reflexively. The recent MI and hemodynamic instability fundamentally change the risk-benefit calculation.

2. Don't underestimate the vasodilatory effects in a patient already requiring vasopressor support. Adenosine-induced hypotension could be catastrophic.

3. Don't ignore the high PVC burden as a marker of electrical instability. This substantially increases the risk of adenosine-induced ventricular arrhythmias.

4. Don't delay cardioversion in pursuit of pharmacologic conversion. The 2025 AHA ACLS guidelines emphasize that unstable patients require prompt cardioversion 9.

Bottom Line

Synchronized cardioversion is the definitive treatment for this patient 2. The combination of recent MI, reduced EF, vasopressor dependence, and high PVC burden creates a perfect storm where adenosine's risks (VF, profound hypotension, MI extension) far outweigh any potential benefits. The FDA contraindications and guideline warnings about acute ischemia and cardiovascular instability apply directly to this clinical scenario 1.